American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
EMERYVILLE, Calif., May 31, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference, taking place on June 6-9, 2017, in New York, NY.
Zogenix Presentation Details
| Date: | Wednesday, June 7, 2017 |
| Time: | 2:00 pm Eastern Time / 11:00 am Pacific Time |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
